Spondyloarthritis & psoriatic arthritis
Efficacy and safety of deucravacitinib, an oral, selective tyrosine kinase 2 inhibitor, in patients with active psoriatic arthritis: 52-week results from the randomised, double-blind, placebo-controlled phase 3 POETYK PsA-1 trial
Authors' conclusion
Deucravacitinib demonstrated superiority vs placebo for clinical responses, patient-reported outcomes, and structural damage inhibition in patients with PsA, with favourable tolerability and safety.
Study context
- Population
- Adults with active PsA naïve to bDMARDs, high-sensitivity CRP ≥ 3 mg/L and ≥ 1 PsA-related hand and/or foot erosion on radiograph
- Participants
- 670 adults
- Comparison
- Deucravacitinib 6 mg orally once daily vs placebo through W16, then all on deucravacitinib through W52
- Primary endpoint
- ACR20 response
- Follow-up
- W16
Methodological detailsdouble-blind, placebo-controlled, phase 3
- Double-blind
- Placebo-controlled
- Phase 3
Primary result
As reported in the abstract
ACR20
P < 0.001
Further findings
Responses with deucravacitinib · W52
- Responses with deucravacitinib were increased at W52; placebo-to-deucravacitinib switchers achieved improvements similar to continuous deucravacitinib
Structural damage · W16 and W52
- Inhibition of structural damage observed at W16 and W52
- Post hoc rank analysis of covariance, no missing data imputation
Deaths
- No deaths occurred
- No imbalances in cardiovascular events, malignancies, or opportunistic infections; no new safety signals
Safety
Serious AEs · W16
Discontinuations due to AEs · W16
- Serious adverse events (AEs): remained low through W52
- Discontinuations due to AEs: remained low through W52
Original publication
Efficacy and safety of deucravacitinib, an oral, selective tyrosine kinase 2 inhibitor, in patients with active psoriatic arthritis: 52-week results from the randomised, double-blind, placebo-controlled phase 3 POETYK PsA-1 trial. Ann Rheum Dis. Published 7 August 2026. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →